肿瘤干细胞标志物CD44v6和CD133在喉鳞癌中的表达及意义

发布时间：2018-06-27 11:06

本文选题：喉鳞状细胞癌 + CD44v6　；参考：《山西医科大学》2012年硕士论文

【摘要】：目的：研究肿瘤干细胞标志物CD44v6和CD133蛋白在喉癌组织与喉癌Hep-2细胞表达的相关性；探讨其与喉癌患者临床病理参数间的关系；分析肿瘤干细胞标志物CD44v6 和CD133蛋白作为喉癌干细胞标志物的合理性。方法：选取病例资料齐全的喉鳞癌患者的组织蜡块53例，收集20例喉癌旁正常组织及培养3组喉癌Hep-2细胞进行实验研究。采用免疫组织化学及免疫细胞化学技术分别检测53例喉鳞癌组织、20例喉癌旁正常组织及3组喉癌Hep-2细胞的CD44v6和CD133蛋白表达情况。采用SPSS17.0统计学软件进行统计学分析，采用χ2检验或精确概率检验法（Fisher′exact test）比较CD44v6和CD133蛋白在喉癌不同临床分型、不同T、N分期及不同分化程度之间的表达差异，检验水准α=0.05，以P0.05为差异有统计学意义。CD44v6和CD133蛋白之间的关联分析采用Spearman秩相关分析，以P0.05为差异有统计学意义。结果：CD44v6蛋白在喉癌组织与正常喉黏膜组织中阳性率分别为75.47%、30%，，有显著性差异（P0.05)；CD133蛋白在喉癌组织与正常喉黏膜组织中阳性率分别为71.69%、25%，有显著性差异（P0.05)。CD44v6蛋白表达阳性率与病理学分级、T分期相关（P0.05)，与临床分型及有无颈淋巴结转移组无相关性（P0.05）。CD133蛋白表达强度与病理分级、T分期及有无淋巴结转移有关（P㩳0.05），与患者的临床分型无关（P㧐0.05）。两者在蛋白表达水平上有明显相关性（P＜0.05），CD44v6和CD133阳性表达组术后生存期均短于阴性组（P＜0.05），但CD133阳性表达组较CD44v6阳性表达组明显。喉癌Hep-2细胞的CD44v6蛋白阳性表达率分别为72%、75%、76%，平均为74.3%；CD133蛋白只在少数细胞中表达，绝大多数细胞不表达，阳性表达率分别为2.33%、2.61%、3.15%，平均为2.70%。结论：肿瘤干细胞标志物CD44v6蛋白在喉癌组织与喉癌Hep-2细胞中有相似的阳性表达率，喉癌Hep-2细胞中CD133蛋白只在少数细胞中表达，大多数细胞不表达；CD44和CD133在喉鳞状细胞癌的发生发展过程中发挥着一定的作用。CD44v6和CD133蛋白表达与喉癌的一些恶性特征有相关性，但是否可以作为喉癌干细胞的标志物尚需更多的实验研究。
[Abstract]:Objective: to study the correlation between the expression of CD44v6 and CD133 protein in laryngeal carcinoma and Hep-2 cells, and to explore the relationship between CD44v6 and CD133 protein and the clinicopathological parameters of laryngeal carcinoma. To analyze the rationality of tumor stem cell markers CD44v6 and CD133 as stem cell markers of laryngeal carcinoma. Methods: 53 cases of laryngeal squamous cell carcinoma (LSCC) were collected from 53 cases of laryngeal squamous cell carcinoma (LSCC), 20 cases of normal tissue adjacent to laryngeal carcinoma and 3 groups of laryngeal carcinoma Hep-2 cells were collected for experimental study. The expression of CD44v6 and CD133 in 53 cases of laryngeal squamous cell carcinoma (LSCC) and 20 cases of normal tissues adjacent to laryngeal carcinoma and 3 groups of laryngeal carcinoma Hep-2 cells were detected by immunohistochemistry and immunocytochemistry respectively. SPSS 17.0 statistical software was used to analyze the expression of CD44v6 and CD133 proteins in different clinical types, stages and differentiation of laryngeal carcinoma by 蠂 2 test or exact probability test. The correlation between CD44v6 and CD133 protein was analyzed by Spearman rank correlation analysis. Results the positive rates of CD44v6 protein in laryngeal carcinoma and normal laryngeal mucosa were 75.47 and 30, respectively (P0.05). The positive rates of CD133 protein in laryngeal carcinoma tissues and normal laryngeal mucosa tissues were 71.690.There was significant difference (P0.05). CD44v6 protein expression was correlated with pathological grade and T stage (P0.05), but had no correlation with clinical type and cervical lymph node metastasis group (P0.05) .CD133. The expression intensity of protein was related to T stage of pathological grade and lymph node metastasis (P0. 05), but not to clinical type (P0. 05). The expression of CD44v6 and CD133 were significantly correlated (P < 0.05). The survival time of CD44v6 and CD133 positive expression group was shorter than that of negative group (P < 0.05), but the CD133 positive expression group was significantly higher than that of CD44v6 positive group (P < 0.05). The positive expression rates of CD44v6 protein in Hep-2 cells were 720.75 and 76.The average expression rate of CD133 was 74.3%. Most of the cells did not express CD44v6. The positive rates of CD44v6 protein were 2.33 ~ 2.61% and 3.15%, with an average of 2.70%. Conclusion: the expression rate of CD44v6 protein in laryngeal carcinoma is similar to that in laryngeal carcinoma Hep-2 cells. CD133 protein is expressed only in a few cells in laryngeal carcinoma Hep-2 cells, but not in most cells. CD44 and CD133 play a certain role in the development of laryngeal squamous cell carcinoma. The expression of CD44v6 and CD133 proteins is related to some malignant features of laryngeal carcinoma. However, more experimental research is needed on whether CD44 and CD133 can be used as markers of laryngeal carcinoma stem cells.
【学位授予单位】：山西医科大学
【学位级别】：硕士
【学位授予年份】：2012
【分类号】：R739.65

【参考文献】